| Year |
Citation |
Score |
| 2014 |
Morgan SS, Cranmer LD. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells. Bmc Research Notes. 7: 812. PMID 25406429 DOI: 10.1186/1756-0500-7-812 |
0.369 |
|
| 2014 |
Morgan SS, Feldman R, Cranmer LD. Identification of putative molecular targets in Merkel cell carcinoma. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E20052 |
0.359 |
|
| 2014 |
Cranmer LD, Morgan SS, Feldman R, Hamid O. Biomarker patterns of metastatic melanoma with implications for therapy. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E20050 |
0.373 |
|
| 2012 |
Cruz-Muñoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O'Connor-McCourt MD, Kerbel RS. Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Research. 72: 4909-19. PMID 22865454 DOI: 10.1158/0008-5472.Can-12-2194 |
0.377 |
|
| 2012 |
Morgan SS, Cranmer LD. Abstract 2820: Vorinostat abrogates ridaforolimus-induced activation of Akt in synovial sarcoma cells: A possible rationale for their synergism Cancer Research. 72: 2820-2820. DOI: 10.1158/1538-7445.Am2012-2820 |
0.413 |
|
| 2011 |
Meuillet EJ, Mash EA, Olsen E, Moses SA, Morgan SS. Abstract A242: A novel AKT inhibitor, PH427, prevents UVB-induced signaling in human squamous skin carcinomas. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A242 |
0.47 |
|
| 2010 |
Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. The Oncologist. 15: 1320-8. PMID 21147868 DOI: 10.1634/Theoncologist.2009-0210 |
0.334 |
|
| 2010 |
Cranmer LD, Jeter JM, Morgan SS, Hersh EM, Stea B. Whole-brain radiation therapy in melanoma: an open question. The Lancet. Oncology. 11: 13; author reply 13-. PMID 20129127 DOI: 10.1016/S1470-2045(09)70346-8 |
0.313 |
|
| Show low-probability matches. |